A Study of MKC-442 in Combination With Other Anti-HIV Drugs
Phase 2
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002412
- Lead Sponsor
- Triangle Pharmaceuticals
- Brief Summary
The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.
- Detailed Description
Patients are randomized to receive either MKC-442 or placebo, along with stavudine(d4T), didanosine(ddI), and hydroxyurea. Patients will be treated and followed for 48 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Dr Robert Wallace
🇺🇸St. Petersburg, Florida, United States